ReviewOncogene2003
Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents.
Review in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed.
- Innovative Therapeutic Approaches for the Treatment of the Ocular Morbidities in Patients with EEC Syndrome.Cells · 2023Review
- Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance.Frontiers in oncology · 2022Review
- DR-5 and DLL-4 mAb Functionalized SLNs of Gamma-Secretase Inhibitors- An Approach for TNBC Treatment.Advanced pharmaceutical bulletin · 2021Review
- DAPT suppresses proliferation and migration of hepatocellular carcinoma by regulating the extracellular matrix and inhibiting the Hes1/PTEN/AKT/mTOR signaling pathway.Journal of gastrointestinal oncology · 2021Article
- MicroRNA-200 family expression analysis in metastatic clear cell renal cell carcinoma patients.Cancer gene therapy · 2020Article
- The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance.Genes & development · 2020Review
- Review
- Review
- ZBP-89 negatively regulates self-renewal of liver cancer stem cells via suppression of Notch1 signaling pathway.Cancer letters · 2020Article
- Dibenzazepine Attenuates Against Cisplatin-Induced Nephrotoxicity in Rats: Involvement of NOTCH Pathway.Frontiers in pharmacology · 2020Article
- Numb inhibits epithelial-mesenchymal transition via RBP-Jκ-dependent Notch1/PTEN/FAK signaling pathway in tongue cancer.BMC cancer · 2019Article
- Systems Biology Approaches and Precision Oral Health: A Circadian Clock Perspective.Frontiers in physiology · 2019Review
- MicroRNA-582-5p suppresses non-small cell lung cancer cells growth and invasion via downregulating NOTCH1.PloS one · 2019Article
- HtrA1 suppresses the growth of pancreatic cancer cells by modulating Notch-1 expression.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2018Article
- RKIP: A Key Regulator in Tumor Metastasis Initiation and Resistance to Apoptosis: Therapeutic Targeting and Impact.Cancers · 2018Review
- Correlation between HGF/c-Met and Notch1 signaling pathways in human gastric cancer cells.Oncology reports · 2018Article
- Notch1 is a prognostic factor that is distinctly activated in the classical and proneural subtype of glioblastoma and that promotes glioma cell survival via the NF-κB(p65) pathway.Cell death & disease · 2018Article
- Article
- Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.Scientific reports · 2017Article
- MicroRNA-200c increases radiosensitivity of human cancer cells with activated EGFR-associated signaling.Oncotarget · 2017Article
61 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Notch signaling controls cell fate decisions including during development and stem cell renewal and differentiation in many postnatal tissues. Increasing evidence suggests that the Notch signaling network is frequently deregulated in human malignancies and that genetic or pharmacological manipulation of Notch signaling is a novel potential strategy for the treatment of human neoplasms. This review article summarizes the most recent preclinical and clinical evidence linking Notch signaling to cancer, delineates questions that remain unanswered and explores potential biopharmacological strategies to manipulate Notch signaling in vivo.
Indexed as
Identifiers
14528285What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.